NCT03244410

Brief Summary

  • immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number (cooper N et al 2006)
  • recent studies have demonstrated that the pathogenesis of ITP envolves multifactorial autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic forms may represent two distinct immunopathological disorders ( cooper N et al 2006) ( Gern Sheimer T 2009 )

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2017

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 7, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 9, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2017

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2019

Completed
Last Updated

August 9, 2017

Status Verified

August 1, 2017

Enrollment Period

1.2 years

First QC Date

August 7, 2017

Last Update Submit

August 7, 2017

Conditions

Thrombocytopenic Purpura

Outcome Measures

Primary Outcomes (1)

  • lymphocyte count in immune thrombocytopenic purpura

    intital lymphocyte counts predictive value in immune thrombocytopenic purpura by complete blood picture

    15 minutes

Study Arms (1)

immune thrombocytopenic purpura

immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture

Diagnostic Test: complete blood picture

Interventions

complete blood pictureDIAGNOSTIC_TEST

complete blood picture

immune thrombocytopenic purpura

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

primary immune Thrombocytopenic Purpura

You may qualify if:

  • Newly diagnosed cases of primary ITP , adults and children.

You may not qualify if:

  • Cases of secondary ITP

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Purpura, Thrombocytopenic

Condition Hierarchy (Ancestors)

PurpuraBlood Coagulation DisordersHematologic DiseasesHemic and Lymphatic DiseasesThrombotic MicroangiopathiesThrombocytopeniaBlood Platelet DisordersCytopeniaImmune System DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsSkin ManifestationsSigns and Symptoms

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principle investigator

Study Record Dates

First Submitted

August 7, 2017

First Posted

August 9, 2017

Study Start

October 1, 2017

Primary Completion

December 1, 2018

Study Completion

January 1, 2019

Last Updated

August 9, 2017

Record last verified: 2017-08